Prescription ·Strong evidence ·Reviewed May 2026
Pioglitazone is an oral thiazolidinedione used with diet and exercise to improve glycemic control in adults with type 2 diabetes. It improves insulin sensitivity but can cause fluid retention, weight gain, heart failure exacerbation, edema, bone fracture risk, and macular edema. It is not used for type 1 diabetes or diabetic ketoacidosis.
The bottom line
Evidence rating strong. Most-documented uses: improves glycemic control in type 2 diabetes, improves insulin sensitivity, can improve some triglyceride and hdl patterns. 3 sources indexed (2005–2025), with 4 interaction records on file.
Core mechanism
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), changing transcription of insulin-responsive genes in adipose tissue, skeletal muscle, and liver. This improves peripheral insulin sensitivity and reduces hepatic glucose output but also promotes adipocyte differentiation and sodium/fluid retention, explaining weight gain and edema. Bone effects are clinically relevant because thiazolidinediones increase fracture risk, particularly in women.1,2
May be taken with or without food. Clinical effect develops gradually over weeks.
Berberine may lower glucose and add to the glucose-lowering effects of Pioglitazone.
Recommendation: Increase glucose monitoring when starting, stopping, or changing the supplement; coordinate diabetes medication adjustments with the prescriber.
Alpha-Lipoic Acid may lower glucose and add to the glucose-lowering effects of Pioglitazone.
Recommendation: Increase glucose monitoring when starting, stopping, or changing the supplement; coordinate diabetes medication adjustments with the prescriber.
St. John's Wort can induce drug-metabolizing enzymes and transporters and may lower Pioglitazone exposure or undermine therapy.
Recommendation: Avoid starting or stopping St. John's Wort without prescriber review while taking Pioglitazone.
Pioglitazone increases fracture risk; correcting vitamin D deficiency is relevant to bone-health risk reduction.
Recommendation: Check 25-hydroxyvitamin D and address bone health in high-risk patients.
Numbered references. Citations throughout the page link here.
Pioglitazone lowered recurrent stroke or MI risk but increased weight gain, edema, and fracture.
Pioglitazone affected secondary macrovascular endpoints but increased edema and heart failure events.
Label describes CHF boxed warning, dosing, edema, fractures, bladder tumor warning, and monitoring.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
